Ipca On Tailspin After Three-Plant FDA Ban
Ipca Laboratories was pummeled on Indian bourses after the US FDA barred all but one product from three of its facilities that have been grappling with compliance-related issues, piling up more pressure on the firm.
You may also be interested in...
Import alert hit-Ipca gets a temporary reprieve from US FDA for supplies of hydroxychloroquine sulphate and chloroquine phosphate, the antimalarials in the spotlight as potential treatments for COVID-19. But with many firms committing to supplies/donations, analysts appear to be tempering enthusiasm for large windfall gains for the Indian firm.
A recent compilation of FDA warning letters shows that data integrity failings continue to plague API and finished drug manufacturing sites in Asia and Europe.
Canada has joined the U.S. in blocking imports of active pharmaceutical ingredients from an Indian plant of Ipca Laboratories.